» Articles » PMID: 28971289

Targeted Metabolomics Identifies Pharmacodynamic Biomarkers for BIO 300 Mitigation of Radiation-Induced Lung Injury

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2017 Oct 4
PMID 28971289
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Biomarkers serve a number of purposes during drug development including defining the natural history of injury/disease, serving as a secondary endpoint or trigger for intervention, and/or aiding in the selection of an effective dose in humans. BIO 300 is a patent-protected pharmaceutical formulation of nanoparticles of synthetic genistein being developed by Humanetics Corporation. The primary goal of this metabolomic discovery experiment was to identify biomarkers that correlate with radiation-induced lung injury and BIO 300 efficacy for mitigating tissue damage based upon the primary endpoint of survival.

Methods: High-throughput targeted metabolomics of lung tissue from male C57L/J mice exposed to 12.5 Gy whole thorax lung irradiation, treated daily with 400 mg/kg BIO 300 for either 2 weeks or 6 weeks starting 24 h post radiation exposure, were assayed at 180 d post-radiation to identify potential biomarkers.

Results: A panel of lung metabolites that are responsive to radiation and able to distinguish an efficacious treatment schedule of BIO 300 from a non-efficacious treatment schedule in terms of 180 d survival were identified.

Conclusions: These metabolites represent potential biomarkers that could be further validated for use in drug development of BIO 300 and in the translation of dose from animal to human.

Citing Articles

The radioprotectant nano-genistein enhances radiotherapy efficacy of lung tumors in mice.

Kaytor M, Serebrenik A, Lapanowski K, McFall D, Jones M, Movsas B Transl Lung Cancer Res. 2023; 12(5):999-1010.

PMID: 37323169 PMC: 10261856. DOI: 10.21037/tlcr-22-856.


A Review of Radiation-Induced Alterations of Multi-Omic Profiles, Radiation Injury Biomarkers, and Countermeasures.

Shakyawar S, Mishra N, Vellichirammal N, Cary L, Helikar T, Powers R Radiat Res. 2022; 199(1):89-111.

PMID: 36368026 PMC: 10279411. DOI: 10.1667/RADE-21-00187.1.


Serum Metabolomic Analysis of Radiation-Induced Lung Injury in Rats.

Feng Y, Gao Y, Tu W, Feng Y, Cao J, Zhang S Dose Response. 2022; 20(1):15593258211067060.

PMID: 35069051 PMC: 8753076. DOI: 10.1177/15593258211067060.


A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury.

Satyamitra M, Cassatt D, Marzella L Radiat Res. 2021; 197(4):408-414.

PMID: 34714907 PMC: 9063325. DOI: 10.1667/RADE-21-00153.1.


Microbiome study in irradiated mice treated with BIO 300, a promising radiation countermeasure.

Cheema A, Li Y, Singh J, Johnson R, Girgis M, Wise S Anim Microbiome. 2021; 3(1):71.

PMID: 34627406 PMC: 8501697. DOI: 10.1186/s42523-021-00132-1.


References
1.
Griese M . Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J. 1999; 13(6):1455-76. DOI: 10.1183/09031936.99.13614779. View

2.
. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

3.
Agrawal A, Kale R . Radiation induced peroxidative damage: mechanism and significance. Indian J Exp Biol. 2001; 39(4):291-309. View

4.
Kolesnick R, Fuks Z . Radiation and ceramide-induced apoptosis. Oncogene. 2003; 22(37):5897-906. DOI: 10.1038/sj.onc.1206702. View

5.
Houjou T, Yamatani K, Nakanishi H, Imagawa M, Shimizu T, Taguchi R . Rapid and selective identification of molecular species in phosphatidylcholine and sphingomyelin by conditional neutral loss scanning and MS3. Rapid Commun Mass Spectrom. 2004; 18(24):3123-30. DOI: 10.1002/rcm.1737. View